In the context of gastric carcinogenesis, Tye et al. (132), using a GC murine model (gp130F/F) displaying elevated gastric TLR2 expression levels, have elegantly shown that genetic and antibody-mediated therapeutic targeting of TLR2 leads to a substantial reduction in stomach size and overall tumor burden, including the number of gastric tumors. This evidence concerns the gene TLR2 and gastric cancer.